Skip to main content

Table 1 Baseline data by group

From: Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4–5: a retrospective single center study

 

Already in VDRA treatment (aVDRA)

Starting VDRA treatment (VDRA+)

No VDRA treatment (VDRA-)

P

N

35

59

52

 

Age (mean, range)

59,4 (19–89)

57,2 (19–86)

65,1 (34–95)*

P < 0.05

Sex (% male)

71

71

63

Ns

Diagnosis

Glomerulonephritis (n)

6

14

9

 

Tubulointerstitiel nephritis (n)

1

1

1

 

Pyeolonephritis (n)

1

0

1

 

Obstructive nephropathy (n)

3

5

3

 

Polycystic (ADPKD) (n)

0

5

4

 

Hypertensive (n)

2

6

3

 

DM type I (n)

0

7

4

 

DM type II (n)

6

4

10

 

Unknown (n)

13

11

13

 

Other (n)

3

6

4

 

Observation time (days)

Total

17490

44282

30157

P < 0.05

Median (range)

500 (67–1603)

751(84–1716)

580 (93–1487)

P < 0.05

Kidney Function

eGFR (ml/min/1.73 m2)

14.8 ± 5.8

16.5 ± 4.3

18.8 ± 10.9

Ns

Creatinine Clearance (ml/min)

19.2 ± 6.5

21.7 ± 15.6

23.8 ± 15.8

Ns

U-Albumin (g/24 h)

1.55 ± 1.96

1.96 ± 1.97

2.41 ± 2.32

Ns

Mineral-Bone

S-calcium (mmol/l)

1.12 ± 0.11*

1.17 ± 0.07

1.21 ± 0.08

P < 0.001

S-phosphate (mmol/l)

1.67 ± 0.50*

1.45 ± 0.32

1.40 ± 0.32

P < 0.005

S-PTH (pmol/l)*

24.0 ± 16.0

21.3 ± 10.6

14.9 ± 10.1*

P < 0.005

Blood pressure

Systolic (mmHg)

147 ± 19

151 ± 20

156 ± 20

Ns

Diastolic (mmHg)

85 ± 13

85 ± 11

82 ± 11

Ns

Medication

Alfacalcidol (μg/week)

3.0 ± 1.7

   

Calcium with Vitamin D (n,(%))

6 (17%)

4 (7%)

12 (23%)

Ns

Phosphate-binder (n,(%))

9 (25%)*

7 (12%)

7 (13%)

P < 0.01

ACEi/ARB (n,(%))

21(60%)1 dual

36 (61%)6 dual

24 (46%) 3 dual

Ns

  1. Included are adult patients with at least one 24 h urine with albuminuria > 0.3 g/d. Mean ± SD if not otherwise stated. * This group differed significantly from the other two.